Abstract
Glioblastoma (GBM) is the most common primary central nervous system malignancy in adults and continues to carry a poor prognosis despite standard of care involving surgical resection and concomitant chemoradiotherapy. Recently, immunotherapy has become a rapidly evolving area of novel therapies for various cancers. For gliomas, antibodies including immune checkpoint inhibitors, such as anti-PD-1, and agents targeting tumor neovascularization were studied, but results from clinical trials show no survival benefit with immunotherapy in GBM.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Immunotherapeutic Strategies for the Treatment of Glioma
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
